期待されるチアゾリジン薬 改訂版 

出版社: フジメディカル出版
著者:
発行日: 2013-05-10
分野: 臨床医学:内科  >  糖尿病
ISBN: 9784862700315
電子書籍版: 2013-05-10 (改訂版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:約3営業日

5,184 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,110 円(税込)

商品紹介

初版発行から6年,新たに15項目を追加した大幅増ページの改訂版。新たなエビデンス,安全性,インクレチン関連薬等との併用,ひとくちコラムなど,チアゾリジン薬(ピオグリタゾン)の最新知見から効果的な使い方までを網羅。

目次

  • 表紙
  • 改訂の序
  • 執筆者一覧
  • 目次
  • カラー図譜
  • 1. 糖尿病におけるインスリン抵抗性と薬物療法
  • わが国の2型糖尿病の特徴
  • ひとくちコラム KCNQ 1
  • 2型糖尿病におけるインスリン抵抗性
  • チアゾリジン薬の作用機序
  • 経口糖尿病治療薬の種類と特性
  • 2. 各種疾患におけるインスリン抵抗性
  • 循環器疾患におけるインスリン抵抗性
  • 高血圧とインスリン抵抗
  • 脂質代謝とインスリン抵抗性
  • 認知症とインスリン抵抗性 - アルツハイマー病を中心に
  • 臓器別のインスリン抵抗性
  • 3. チアゾリジン薬が期待される理由
  • 血糖改善作用 - 長期の血糖管理
  • 膵保護作用
  • 糖尿病発症抑制
  • 腎保護作用
  • 脂質代謝異常改善作用
  • 抗動脈硬化作用
  • アディポカインに対する作用 - アディポネクチンをはじめとして
  • ひとくちコラム オスモチン
  • 脂肪肝に対する作用
  • ひとくちコラム 肝臓での酸化ストレス・小胞体ストレスへ及ぼす作用
  • 4. チアゾリジンのわが国における臨床研究
  • 炎症および酸化ストレス軽減作用
  • ひとくちコラム PI3Kγ阻害によるインスリン抵抗性改善の可能性
  • IMTの減少作用および血糖低下に依存しない抗動脈硬化作用
  • 冠動脈疾患病態改善作用
  • 微量アルブミン尿への影響
  • 5. 大規模試験から
  • PRACTICAL
  • PROactive Study
  • ひとくちコラム Legacy effect
  • CHICAGO Study
  • PERISCOPE study
  • J-DOIT3
  • ACT NOW
  • 6. チアゾリジンの安全性
  • 浮腫
  • 体重増加
  • 骨折
  • ピオグリタゾンとロシグリタゾンの相違 (安全性)
  • 膀胱癌
  • 7. チアゾリジン薬の効果的な使い方
  • 単独投与
  • 他剤との併用
  • SU薬, グリニド薬
  • ビグアナイド薬
  • インクレチン薬, α-グルコシダーゼ阻害薬
  • インスリン製剤
  • 心疾患合併例
  • 8. PPARγの最新動向
  • PPAR標的薬の開発動向
  • PPARγをめぐる基礎研究の進展 - エピゲノム解析をはじめとして
  • 索引
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 糖尿病におけるインスリン抵抗性と薬物療法

P.21 掲載の参考文献
P.23 掲載の参考文献
P.31 掲載の参考文献
P.41 掲載の参考文献
1) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
4) Lehmann JM et al:An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPARγ). J Biol Chem 270:12953-12956, 1995
P.48 掲載の参考文献
8) Knowler WC et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
10) 加来浩平ほか:2型糖尿病におけるメトホルミンの使用実態に関する観察研究(MORE study). 糖尿病 49(5):325-331, 2006
13) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005

2. 各種疾患におけるインスリン抵抗性

P.57 掲載の参考文献
1) 伊藤千賀子: OGTTの経年観察結果と2型糖尿病. 日本臨床 60(Suppl 8):111-118, 2002
2) Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology:Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999
10) 動脈硬化性疾患予防ガイドライン 2012年版. 日本動脈硬化学会
11) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
P.62 掲載の参考文献
2) 竹内 宏ほか: 日本人におけるMetabolic Syndrome とインスリン抵抗性の検討-端野・壮瞥町研究- . 糖尿病 46:739-744, 2003
6) Togashi N et al:Effects of TNF-α-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39[part 2]:578-580, 2002
11) Ogiwara T et al:Clinical outcomes in hypertensive patients with high cardiovascular risks: principal results of candesartan antihypertensive survival evaluation in Japan(CASE-J) Study. J Hypertens 24 Suppl (6):30, 2006
P.69 掲載の参考文献
7) 島野 仁:脂質代謝とインスリン抵抗性の新しい視点-臓器蓄積脂肪の量と質-. 外科と代謝・栄養 44:41-47, 2010
P.74 掲載の参考文献
P.80 掲載の参考文献

3. チアゾリジン薬が期待される理由

P.90 掲載の参考文献
5) Kahn SE et al:Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
8) Charbonnel B et al:PROactive investigators. Long-term glycaemic effects of pioglitazone in triple oral therapy:results from PROactive. Diabetologia 49 (suppl 1):488-489, 2006
10) Rosenstock J et al:Efficacy and safety of pioglitazone in type 2 diabetes:a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 56:251-257, 2002
P.99 掲載の参考文献
2) El-Assaad W et al:Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death. Endocrinology 144:4154-4163, 2003
3) Patane G et al:Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-acitivated receptor-γinhibition. Diabetes 51:2749-2756, 2002
6) Ihara Y et al:Hyperglycemia causes oxidative stress in pancreatic β-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927-932, 1999
7) Ishida H et al:Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice:possible protection of βcells from oxidative stress. Metabolism 53:488-494, 2004
8) Gupta D et al:In vivo and in vitro studies of a functional peroxisome proliferator-activated receptorγresponse element in the mouse pdx-1 promoter. J Biol Chem 283:32462-32470, 2008
10) Kanda Y et al:Molecular mechanism by which pioglitazone preserves pancreatic β-cells in obese diabetic mice:evidence for acute and chronic actions as a PPARγagonist. Am J physiol Endocrinol Metab 298:E278-286, 2010
12) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
13) Gastaldelli A et al:Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 292:E871-883, 2007
P.108 掲載の参考文献
1) Buchanan TA et al:Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
4) Knowler WC et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
5) Knowler WC et al:Prevention of type 2 diabetes with troglitazone in the Diabete Prevention Program. Diabetes 54:1150-1156, 2005
7) DeFronzo RA et al:Presented at the 69th ADA Scientific Session, ACT NOW study.
P.114 掲載の参考文献
19) Pollex RL et al:Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 21:166-171, 2007
20) Jorsal A et al:The PPARγ2 Pro12 Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Molecular Genetics and Metabolism 94:347-351, 2008
22) Yamauchi et al:The mechanism by which both heterozygous peroxisome proliferator activated receptor gamma (PPAR gamma) deficiency and PPAR gamma agonist improve insulin resistance. J Biol Chem 276:41245-41254, 2001
P.122 掲載の参考文献
3) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
9) Chawla A et al:A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001
P.126 掲載の参考文献
P.135 掲載の参考文献
11) Qiang L et al:Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell 150(3):620-632, 2012
13) Erdmann E et al; PROactive Investigators:The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction:results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49:1772-1780, 2007
P.137 掲載の参考文献
P.143 掲載の参考文献
2) Ludwig J et al:Nonalcoholic steatohepatitis:Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980
5) 石井裕正, 奥山哲二:非アルコール性脂肪性肝炎. 日本臨床 8:28-31, 1995
6) 石井裕正, 横山顕: アルコール性肝障害. 治療78(臨時増刊号):636-638, 1995
9) Fatty Liver Disease:NASH and Related Disorders. Farrell GC et al eds. Malden, MA, blackwell Publishing, 2005, pp1-319
10) McCullough AJ:The epidemiology and risk factors of NASH. In:Fatty Liver Disease:NASH and Related Disorders. Farrell GC et al eds. Malden, MA, Blackwell Publishing, 2005, pp23-37
17) Bacon BR et al:Nonalcoholic steatohepatitis:an expanded clinical entity. Gastroenterology 107:1103-1109, 1994
33) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910, 2001, [Erratum, Lancet 357:1890, 2001]
P.147 掲載の参考文献

4. チアゾリジンのわが国における臨床研究

P.154 掲載の参考文献
4) Kuboki K et al:Two oxidative stress markers and high-sensitivity C-reactive protein in patients with type 2 diabetes-effects of pioglitazone treatment-. In:Focus on Diabetes Mellitus Research. AM Ford(eds), Nova Biomedical Books, NY, USA, 2005, pp17-32
11) Moore KJ et al:The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47, 2001
12) Pascual G et al:A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763, 2005
16) Pratico D et al:IPF2α-I:an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 95:3449-3454, 1998
P.157 掲載の参考文献
P.161 掲載の参考文献
4) Nagy L et al:Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-240, 1998
5) Tontonoz P et al:PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
6) Spiegelman BM:PPARγ in monocytes:less pain, any gain? Cell 93(2):153-155, 1998
7) Marx N et al:PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression:PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546-951, 1999
8) Moore KJ et al:The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47, 2001
9) Chawla A et al:PPAR-γdependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52, 2001
P.165 掲載の参考文献
1) Murakami T et al:Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 84:92-94, 1999
2) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomized controlled trial. Lancet 366:1279-1289, 2005
P.171 掲載の参考文献
10) Hu YY et al:Hydrochloride pioglitazone decreases urinary TGF-β excretion in type 2 diabetics. Eur J Clin Invest 40:571-574, 2010

5. 大規模試験から

P.183 掲載の参考文献
P.193 掲載の参考文献
P.195 掲載の参考文献
P.203 掲載の参考文献
P.208 掲載の参考文献
P.216 掲載の参考文献
P.221 掲載の参考文献

6. チアゾリジンの安全性

P.229 掲載の参考文献
7) Guan Y et al:Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866, 2005
8) Zhang H et al:Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102:9406-9411, 2005
9) Helledie T et al:The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor γ through an intronic response element functionally conserved between humans and rodents. J Biol Chem 277:26821-26830, 2002
P.234 掲載の参考文献
2) Auwerx J:PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
3) Adams M et al:Activators of peroxisome proliferator-activated receptor γ have depot specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
P.241 掲載の参考文献
1) Kahn SE et al:Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
4) Akune T et al:PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855, 2004
5) Wan Y et al:PPAR-γ regulates osteoclastogenesis in mice. Nat Med 13:1496-1503, 2007
8) Rubin GL et al:Peroxisome proliferator-activated receptorr ligands inhibit estrogen biosynthesis in human breast adipose tissue:possible implications for breast cancer therapy. Cancer Res 60:1604-1608, 2000
9) Lecka-Czernik B et al:Activation of peroxisome proliferator-activated receptor γ(PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903-911, 2007
11) Grey A et al:The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310, 2007
P.249 掲載の参考文献
P.256 掲載の参考文献

7. チアゾリジン薬の効果的な使い方

P.261 掲載の参考文献
P.268 掲載の参考文献
P.277 掲載の参考文献
P.283 掲載の参考文献
7) ジャヌビア錠インタビューフォーム
8) 繁田幸男ほか: 2型糖尿病に対するインスリン抵抗性改善薬ピオグリタゾンのボグリボースとの併用投与による臨床評価-プラセボを対照薬とした二重盲検比較試験. 医学のあゆみ 206:297-319, 2003
9) 横山宏樹ほか: 2型糖尿病におけるピオグリタゾンとアカルボースの併用による抗動脈硬化効果. 糖尿病 49:197-204, 2006
P.288 掲載の参考文献
P.300 掲載の参考文献
2) Anderson HV et al:A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 39:1096-1103, 2002
9) CABRI Trial Participants:First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation). Circulation 93:847, 1996

8. PPARγの最新動向

P.307 掲載の参考文献
4) Guerre-Millo M et al:Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
5) Riserus U et al:Activation of peroxisome proliferator-activated receptor (PPAR)σ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57:332-339, 2008
6) Henry RR et al:Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY):a phase II, randomised, dose-ranging study. Lancet 374:126-135, 2009
7) Choi JH et al:Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477:477-481, 2011
P.319 掲載の参考文献
7) Choi JH et al:Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477:477-481, 2011
8) Qiang L et al:Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell 150:620-632, 2012
19) Siersbaek MS et al:Genome-wide profiling of PPARγ in primary epididymal, inguinal, and brown adipocytes reveals depot-selective binding correlated with gene expression. Mol Cell Biol 32:3452-3463, 2012
34) Ohno H et al:PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab 15:395-404, 2012
37) Cipolletta D et al:PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486:549-553, 2012
38) Jonker JW et al:A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485:391-394, 2012
39) Dutchak PA et al:Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones. Cell 148:556-567, 2012
40) Wei W et al:Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci USA Published Online First:6 February 2012. doi:10.1073/pnas. 1200797109
43) Villanueva CJ et al:Adipose Subtype-Selective Recruitment of TLE3 or Prdm16 by PPARγ Specifies Lipid Storage versus Thermogenic Gene Programs. Cell Metab 17:423-435, 2013
48) Lee Y-H et al:In Vivo Identification of Bipotential Adipocyte Progenitors Recruited by β 3-Adrenoceptor Activation and High-Fat Feeding. Cell Metab 15:480-491, 2012
51) Ryan KK et al:A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med 17:623-626, 2011
52) Lu M et al:Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17:618-622, 2011
53) Endo Y et al:Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling. Cell Metab 13:550-561, 2011

最近チェックした商品履歴

Loading...